Frontiers in Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (20 June 2022) | Viewed by 30697
Special Issue Editor
Interests: biliary tract cancers; cholangiocarcinoma; hepatocellular cancer; pancreatic cancer; drug development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic adenocarcinoma is an aggressive malignancy associated with poor prognosis and is the fourth most common cause of cancer death in the United States. Surgery is the only curative option; however, only 20%–30% present at resectable disease at initial diagnosis. There has been advancement in the understanding of pancreatic carcinogenesis and the development of novel therapeutic agents, including chemotherapy and targeted therapies. Neoadjuvant therapy is being increasingly utilized for treatment of pancreatic cancer for better selection of patients undergoing resection.
The objectives of the current Special Issue of Cancers is to highlight both original articles and reviews addressing the current management strategies of pancreatic cancer, including surgery, radiation therapy and systemic therapies. The current issue will include recent advancements in the understanding of the origin and progression of pancreatic cancer and development of novel chemotherapeutic, immunotherapeutic and targeted therapeutic agents.
Dr. Amit Mahipal
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.